By proceeding, you agree to our Terms of Use and Privacy Policy.
The Leading TGF-ß for Immuno-Oncology Summit Returns Exclusively Dedicated to Exploring the Role of TGF-ß in Cancer Therapeutics It is evident that TGF-ß holds exciting therapeutic promise to IO drug developers but with the complexity of this target, there are still many hurdles to overcome.
Get the latest clinical updates from large pharma giants such as Novartis, Oncotelic Therapeutics, Sanofi and emerging biotechs like Transcenta’s and Lassen Therapeutics.
This three-day event will explore TGF-? role in the immuno-oncology space from biology, translational modelling, biomarkers and clinical trail design perspectives.
If you wish to get core understing on TGF-? function and its biology, its clinical implications and overcoming toxicity issues - this event is a must-attend!
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Make faster and better informed drug development decisions In partnership with the world’s leading drug development experts to help you keep up with the pace of preclinical and clinical research developments.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.